Literature DB >> 35403140

High Expression of PEA15 Is Associated With Patient Survival in Malignant Pleural Mesothelioma.

Shajedul Islam1,2, Takao Kitagawa1, Yasuhiro Kuramitsu1.   

Abstract

Background/Aim: Malignant pleural mesothelioma (MPM) is a rare but very aggressive tumor that is primarily pleural in origin. The 5-year overall survival rate of patients with MPM has not improved despite therapeutic advances. Therefore, biomarker discovery to identify premalignant or early malignant tumors of the mesothelium are crucial. PEA15 is a cytoplasmic protein that is involved in various human malignancies, including MPM. However, the clinicopathological involvement of PEA15 in MPM has not yet been documented. Materials and
Methods: The Oncomine database and GEPIA2 platform were used to analyze PEA15 mRNA expression and patient survival in patients with MPM.
Results: PEA15 was found to be significantly up-regulated in MPM, and this up-regulation inversely correlated with prolonged patient survival. Further, PEA15 expression was found to be increased in other cancer tissues without affecting overall survival.
Conclusion: PEA15 may represent a new potential prognostic biomarker in MPM patients. Copyright 2021, International Institute of Anticancer Research.

Entities:  

Keywords:  Mesothelioma; PEA15; bioinformatics; proteomics

Year:  2021        PMID: 35403140      PMCID: PMC8988953          DOI: 10.21873/cdp.10049

Source DB:  PubMed          Journal:  Cancer Diagn Progn        ISSN: 2732-7787


  16 in total

1.  PEA‑15 contributes to the clinicopathology and AKT‑regulated cisplatin resistance in gastric cancer.

Authors:  Xian Jiang; Changlu Zhang; Weidong Li; Dalei Jiang; Zheng Wei; Mei Lv; Xiangjun Xie; Xueying Sun
Journal:  Oncol Rep       Date:  2018-12-18       Impact factor: 3.906

2.  Up-regulation of DDX39 in human malignant pleural mesothelioma cell lines compared to normal pleural mesothelial cells.

Authors:  Yasuhiro Kuramitsu; Waka Tominaga; Byron Baron; Kazuhiro Tokuda; Yufeng Wang; Takao Kitagawa; Kazuyuki Nakamura
Journal:  Anticancer Res       Date:  2013-06       Impact factor: 2.480

3.  MicroRNA-132 targets PEA-15 and suppresses the progression of astrocytoma in vitro.

Authors:  Fei Geng; Jian-Lin Wu; Gui-Feng Lu; Zhi-Ping Liang; Zhuo-Li Duan; Xi Gu
Journal:  J Neurooncol       Date:  2016-06-13       Impact factor: 4.130

4.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.

Authors:  Zefang Tang; Boxi Kang; Chenwei Li; Tianxiang Chen; Zemin Zhang
Journal:  Nucleic Acids Res       Date:  2019-07-02       Impact factor: 16.971

5.  Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin.

Authors:  Shahana Dilruba; Alessia Grondana; Anke C Schiedel; Naoto T Ueno; Chandra Bartholomeusz; Jindrich Cinatl; Katie-May McLaughlin; Mark N Wass; Martin Michaelis; Ganna V Kalayda
Journal:  Cells       Date:  2020-02-24       Impact factor: 6.600

6.  Phosphorylation of PED/PEA-15 at Ser116 and phosphorylation of p27 at Thr187 indicates a poor prognosis in hepatocellular carcinoma.

Authors:  Yifeng Wu; Xianpeng Li; Mingliang Chen; Zhikun Liu; Xuanyu Zhang; Shusen Zheng; Xiao Xu
Journal:  Oncol Lett       Date:  2021-01-06       Impact factor: 2.967

7.  Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Authors:  Cristina Quintavalle; Sravanth Kumar Hindupur; Luca Quagliata; Pierlorenzo Pallante; Cecilia Nigro; Gerolama Condorelli; Jesper Bøje Andersen; Katrin Elisabeth Tagscherer; Wilfried Roth; Francesco Beguinot; Markus Hermann Heim; Charlotte Kiu Yan Ng; Salvatore Piscuoglio; Matthias Sebastian Matter
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

8.  PEA15 promotes liver metastasis of colorectal cancer by upregulating the ERK/MAPK signaling pathway.

Authors:  Bo Tang; Wenjin Liang; Yong Liao; Zeming Li; Yan Wang; Chao Yan
Journal:  Oncol Rep       Date:  2018-10-25       Impact factor: 3.906

9.  The microRNA212 regulated PEA15 promotes ovarian cancer progression by inhibiting of apoptosis.

Authors:  Yonghong Luo; Chuanchuan Fang; Lan Jin; Huafeng Ding; Yuanyuan Lyu; Guantai Ni
Journal:  J Cancer       Date:  2020-01-13       Impact factor: 4.207

10.  ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15.

Authors:  Shuang Wang; Caixia Wang; Yuexin Hu; Xiao Li; Shan Jin; Ouxuan Liu; Rui Gou; Yuan Zhuang; Qian Guo; Xin Nie; Liancheng Zhu; Juanjuan Liu; Bei Lin
Journal:  J Exp Clin Cancer Res       Date:  2020-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.